All News


All series


All All News

The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.

Although the wounds inflicted by cancer may not always be externally visible, they are there. Our society is full of those scarred for life, they are cancer's walking wounded.